Journal Title：Cancer Gene Therapy

Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair.

Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.

《癌癥基因治療》是癌癥研究人員和臨床醫(yī)生必不可少的基因和細(xì)胞治療資源，讓讀者了解癌癥基因和細(xì)胞治療的最新發(fā)展。該期刊發(fā)表原創(chuàng)實(shí)驗(yàn)室和臨床研究論文、病例報(bào)告和評(píng)論文章。出版主題包括 RNAi 方法、耐藥性、造血祖細(xì)胞基因轉(zhuǎn)移、癌癥干細(xì)胞、細(xì)胞療法、同源重組、核酶技術(shù)、反義技術(shù)、腫瘤免疫治療和腫瘤抑制因子、轉(zhuǎn)化研究、癌癥治療、基因傳遞系統(tǒng)（病毒和非病毒）、抗基因治療（反義、siRNA 和核酶）、細(xì)胞凋亡；機(jī)制和療法、疫苗開(kāi)發(fā)、免疫學(xué)和免疫治療、DNA 合成和修復(fù)。

《癌癥基因治療》發(fā)表應(yīng)用于癌癥研究的基因轉(zhuǎn)移/基因治療和細(xì)胞療法領(lǐng)域的實(shí)驗(yàn)室研究、臨床前研究和臨床試驗(yàn)的結(jié)果。發(fā)表的文章類(lèi)型包括原創(chuàng)研究文章；病例報(bào)告；簡(jiǎn)短通訊；藥物耐藥性/敏感性、基因治療、細(xì)胞治療、腫瘤抑制和抗癌基因治療、細(xì)胞因子/腫瘤免疫治療等主要領(lǐng)域的評(píng)論文章；行業(yè)觀點(diǎn)；以及致編輯的信。

Cancer Gene Therapy創(chuàng)刊于1999年，由Springer Nature出版商出版，收稿方向涵蓋醫(yī)學(xué) - 生物工程與應(yīng)用微生物全領(lǐng)域，此刊是中等級(jí)別的SCI期刊，所以過(guò)審相對(duì)來(lái)講不是特別難，但是該刊專(zhuān)業(yè)認(rèn)可度不錯(cuò)，仍然是一本值得選擇的SCI期刊 。平均審稿速度 偏慢,4-8周 ，影響因子指數(shù)4.8，該期刊近期沒(méi)有被列入國(guó)際期刊預(yù)警名單，廣大學(xué)者值得一試。